Innovent Biologics, Inc. announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI310 in combination with sintilimab for the treatment of patients with recurrent or metastatic cervical cancer. The NMPA BTD for IBI310 was based on results from First part of a…
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI310 in combination with sintilimab for the treatment of patients with recurrent or metastatic cervical cancer.
- The NMPA BTD for IBI310 was based on results from First part of a….
- eTurboNews greinar eru eingöngu fyrir áskrifendur.